An Open Label Trial of Azithromycin in Chronic Productive Cough (AZCC)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02196493|
Recruitment Status : Unknown
Verified February 2016 by University of Nottingham.
Recruitment status was: Recruiting
First Posted : July 22, 2014
Last Update Posted : February 18, 2016
We have noticed a group of patients presenting with a longstanding wet cough which has often been treated as asthma. The cough is productive of sputum which frequently contains bacteria, but does not resolve with standard antibiotic treatment.
A very similar cough is seen in subjects who smoke, have exposure to airbourne dusts or chemicals or have a condition known as bronchiectasis, but these problems have already been excluded.
We have found that prolonged treatment with an antibiotic called azithromycin is very effective but using azithromycin in this way is not licensed and there is currently no trial evidence to support its use.
This research will evaluate the clinical benefit of low dose azithromycin to determine if this is an effective and safe treatment for these patients. It will also involve a detailed investigation of these patients to determine whether they have enough in common to believe we are describing a new condition.
|Condition or disease||Intervention/treatment||Phase|
|Chronic Cough||Drug: Azithromycin||Phase 3|
We and others have observed a cohort of patients, mainly referred with either poorly controlled asthma despite high dose treatment or suspected bronchiectasis, who give a history of chronic (often 3 months or more) productive cough which improves with antibiotic treatment but quickly relapses. Most deny wheeze and on examination there are often transmitted sounds from mucus in the large airways but no expiratory wheeze typical of asthma. Investigations including spirometry, bronchial challenges, chest X-ray, screen for immunodeficiency and high resolution CT (HRCT) scan exclude recognised causes of productive cough but sputum culture is often positive for Haemophilus influenzae although sometimes demonstrates normal respiratory flora despite being markedly purulent.
Due to their efficacy in cystic fibrosis and bronchiectasis we have empirically tried treatment with low dose macrolide antibiotics over 3-6 months often with dramatic benefit. This is however an unproven and unlicensed indication which needs to be more thoroughly evaluated.
The key objective of the study is to determine if 12 weeks treatment of patients with chronic productive cough with low dose azithromycin is both effective and safe.
The secondary objectives of the study are to describe the clinical and pathological features of a cohort of patients who present with chronic productive cough (with no evidence of bronchiectasis, smoking-related chronic bronchitis or immunodeficiency) to determine if these are sufficiently similar to justify a new diagnostic label.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||50 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||An Open Label Trial of Azithromycin in Chronic Productive Cough|
|Study Start Date :||December 2013|
|Estimated Primary Completion Date :||December 2016|
|Estimated Study Completion Date :||December 2016|
250mg azithromycin three times weekly for 12 weeks
250mg azithromycin three times per week for 12 weeks
Other Name: Zithromax
- Change from baseline in cough on the Leicester Cough Questionnaire (LCQ) score at week 12 [ Time Frame: 12 weeks after treatment started ]
- Change from baseline in sputum colour (as per previously validated commercially available graded sputum colour chart) at week 12 [ Time Frame: 12 weeks after treatment started ]
- Change from baseline in exhaled nitric oxide level (ppm) at week 24 [ Time Frame: 12 weeks after treatment started ]
- Change from baseline in FEV1 (ml) at week 24 [ Time Frame: 12 weeks after treatment started ]
- Change from baseline in sputum volume (ml) at week 12 [ Time Frame: 12 weeks after treatment started ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02196493
|Contact: Matthew Martin, MBChBfirstname.lastname@example.org|
|Respiratory Research Unit||Recruiting|
|Nottingham, Nottinghamshire, United Kingdom, NG5 1PB|
|Contact: Matthew Martin, MBChB 01158231935|
|Principal Investigator: Tim Harrison, MD, FRCP|
|Sub-Investigator: Matthew Martin, MBChB MRCP|
|Principal Investigator:||Tim Harrison, MD, FRCP||University of Nottingham|